In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1765-1772

  Modesitt, S C ^a   Ramirez, P ^a   Zu, Z ^a   Bodurka Bevers, D ^a   Gershenson, D ^a   Wolf, J K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; PROTEIN P16; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DNA, COMPLEMENTARY; FEMALE; GENES, P16; GENES, P53; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034905621     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Carcinoma of the ovary
2. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus
3. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
4. The p53 tumor suppressor gene frequently is altered in gynecologic cancers
5. Overexpression and mutation of p53 in epithelial ovarian cancer
6. Studies on the molecular mechanism of growth inhibition with p53 adenoviral construct in human ovarian cancer
7. Adenovirus-based p53 gene therapy in ovarian cancer
8. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse
9. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer
10. KIP1 in inducing cell cycle arrest, apoptosis, and inhibition of tumor-igenicity
11. Feasibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay
12. Rare mutations and no hypermethylation at the CDK2A locus in epithelial ovarian tumors
13. LOH and mutation analysis of CDKN2 in primary human ovarian cancers
14. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors
15. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2
16. High frequency of chromosome 9 deletion in ovarian cancer: Evidence for three tumour-suppressor loci
17. 1NK4 in human ovarian tumours
18. INK4 in ovarian cancer is associated with progression and unfavourable prognosis
19. High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer cell lines
20. Restoration of wild type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
21. INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer
22. INK4A expression adenovirus vector to suppress pancreas cancer cell proliferation
23. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck
24. INK4A gene
25. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
26. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
27. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
28. 1 arrest in human glioma cells
29. 1 arrest and protects from paclitaxel and topotecan: Implications for therapy
30. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel